You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
Scientists first isolated Zika virus in 1947, but the disease it caused in humans was considered mild: It did nothing to 80% of the people it infected, and the ones who had symptoms only had temporary fevers and rashes. But last year, a high number of cases of brain-damaging microcephaly in newborns began to surface in Brazil in lockstep with the arrival of the Zika virus, which is spread by mosquitoes. The World Health Organization on 1 February declared these clusters of disease a "public health emergency of international concern," and a rush of vaccinemakers has jumped into the race to develop a preventive. Vaccines exist against several other flaviviruses, the family Zika belongs to, and experts predict that this won't be a major scientific challenge. They also say it may be possible to piggyback on the other flavivirus vaccines, like ones made for dengue and yellow fever. Then again, vaccine R&D takes time, and because this effort is starting from scratch, researchers say it will take at least a few years before a vaccine can prove itself safe and effective in large human efficacy studies.
